APM
TRIL

Avidity Partners Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Avidity Partners Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,105,000
Closed -$39.8M – 132
2021
Q2 		$39.8M Buy
4,105,000
+90,000
+2% +$847K 1.08% 35
2021
Q1 		$43.1M Buy
4,015,000
+829,800
+26% +$10.3M 1.19% 30
2020
Q4 		$46.9M Buy
3,185,200
+1,439,200
+82% +$20.8M 1.52% 20
2020
Q3 		$24.8M Buy
+1,746,000
New +$17.4M 1.15% 28

Other funds holding TRIL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Avidity Partners Management's TRIL Position: Q3 2021 in Review

Avidity Partners Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 4,105,000 shares — an estimated $39.8M sold.

Avidity Partners Management first reported a position in TRIL in Q3 2020 and held it in 4 quarters. The position peaked at $46.9M in Q4 2020. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Avidity Partners Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Avidity Partners Management sold 4,105,000 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $39.8M.
  • Avidity Partners Management first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 4 quarters.
  • Avidity Partners Management's Trillium Therapeutics Inc. position peaked at $46.9M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.